The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology

蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖

• 批准号: 10623252
• 负责人: Nina Bhardwaj
• 金额: $ 56.69万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10623252
• 关键词: Address; Basic Science; Cancer Intervention; Career Mobility; Clinical; Clinical Investigator; Clinical Oncology; Clinical Research; Clinical Sciences; Clinical Trials; Communities; Data Science; Development; Doctor of Philosophy; Education; Entrepreneurship; Environment; Evaluation; Faculty; Funding; Future; Goals; Immunotherapeutic agent; Individual; Institution; Interdisciplinary Communication; Intervention Trial; Justice; K-Series Research Career Programs; Knowledge; Leadership; Learning; Malignant Neoplasms; Master of Science; Medicine; Mentored Clinical Scientist Development Program; Mentors; Methodology; Oncologist; Oncology; Outcome; Pharmaceutical Preparations; Population; Positioning Attribute; Professional Competence; Program Development; Research; Research Activity; Research Personnel; Research Training; Science; Social Responsibility; Structure; Talents; Therapeutic; Training; Translational Research; United States National Institutes of Health; anti-racism; anticancer research; cancer immunotherapeutics; cancer therapy; career; career development; drug discovery; education research; equity, diversity, and inclusion; graduate school; improved; innovation; medical specialties; multidisciplinary; multiple omics; next generation; novel; patient oriented; patient oriented research; pedagogy; precision medicine; programs; recruit; resilience; response; success; tool

SUMMARY/ABSTRACT: The purpose of our proposed Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology (K12) is to catalyze the clinical and translational research career development of inspired clinical oncologists from diverse oncology specialties and backgrounds, to become future innovative, scientifically grounded and impactful leaders in clinical cancer research and interventional trials. The intent of our K12 is to advance the careers of the next generation of independently funded interdisciplinary Scholars, armed with the methodologic and analytical acumen, scientific knowledge, teaming capacity and career skills required to successfully address specific unmet needs in cancer treatment, which significantly impact our catchment relevant population. Our strongly mentored career development 3 year program for early stage (junior faculty) investigators, will capitalize upon the Tisch Cancer Institute's expertise in cancer immunotherapeutics, novel correlates of immunotherapeutic response, integrative multi- omic platforms to inform drug repositioning approaches; outstanding cadre of Clinical and Translational Mentors; diverse pool of compelling Scholars, and an academically rigorous training environment that prepares the most compelling MD, or MD/PhD junior faculty in clinical oncology for careers in patient oriented research. Our curricular and mentored research activities will additionally leverage institutional strengths in Data Science, Drug Discovery and Precision Medicine: clinical trial methodology; innovative clinical and translational research education and pedagogy, including opportunities to earn a Master's of Science or PhD in Clinical Research, offered through the Clinical Research Education Program in the Graduate School of Biomedical Sciences and CTSA Center for Patient Oriented Research Training, Education and Development (CePORTED); and align with the NIH UNITE and our institutional anti-racist agenda and commitment to recruit and retain talented underrepresented individuals in medicine and science (URiMS). To accomplish our goals, we will pursue the following specific aims: Aim 1: Champion a structured, educational, scholar specific development program to prepare clinical oncologists to conduct cutting edge, hypothesis -driven and practice changing research in cancer therapeutics; Aim 2: Provide Co-Mentored (Basic and Clinical science faculty) and community informed clinical trial research opportunities in therapeutic innovation; Aim 3: Build a patient oriented cancer research learning culture to advance therapeutic innovation by delivering cutting edge multidisciplinary career development opportunities to advance team science, leadership, cross-disciplinary communication, resilience, and entrepreneurship; Aim 4: Advance justice, equity, diversity and inclusion as core tenets of socially responsible clinical investigators; and Aim 5: Implement a comprehensive, rigorous and quality improvement approach, to program, trainee and mentor evaluation, utilizing novel tools, to track milestones as well as outcome metrics of success.

摘要/摘要：我们提议的 Tisch 癌症研究所 (TCI) Paul Calabresi K12 的目的 临床肿瘤学职业发展奖（K12）旨在促进临床和转化研究 来自不同肿瘤学专业和背景的富有灵感的临床肿瘤学家的职业发展， 成为临床癌症研究领域未来创新、有科学依据和有影响力的领导者 介入试验。我们 K12 的目的是促进下一代独立人士的职业生涯 资助具有方法论和分析能力、科学知识的跨学科学者， 成功解决癌症治疗中未满足的特定需求所需的团队能力和职业技能， 这对我们流域的相关人口产生了重大影响。我们大力指导的职业发展 3 早期（初级教师）研究人员的年计划将利用蒂施癌症研究所的 癌症免疫治疗方面的专业知识、免疫治疗反应的新相关性、综合多 组学平台为药物重新定位方法提供信息；临床及转化优秀骨干 导师；多元化的引人注目的学者队伍，以及学术严谨的培训环境，为 临床肿瘤学领域最引人注目的医学博士或医学博士/博士初级教师，致力于以患者为导向的研究职业。 我们的课程和指导研究活动将另外利用数据科学领域的机构优势， 药物发现和精准医学：临床试验方法；创新的临床和转化研究 教育和教学法，包括获得临床研究理学硕士或博士学位的机会， 通过生物医学科学研究生院的临床研究教育计划提供 CTSA 以患者为导向的研究培训、教育和发展中心 (CePORTED)；并对齐 与 NIH UNITE 和我们机构的反种族主义议程以及招募和留住人才的承诺 医学和科学领域代表性不足的个人 (URiMS)。为了实现我们的目标，我们将追求 以下具体目标： 目标 1：倡导一个结构化的、教育性的、针对学者的发展计划 准备临床肿瘤学家进行前沿的、假设驱动的和实践改变的研究 癌症治疗；目标 2：提供共同指导（基础和临床科学教师）和社区信息 治疗创新的临床试验研究机会；目标 3：建立以患者为导向的癌症研究 学习文化通过提供前沿的多学科职业来推进治疗创新 促进团队科学、领导力、跨学科沟通、复原力的发展机会， 和创业精神；目标 4：推进正义、公平、多样性和包容性，将其作为社会发展的核心原则 负责的临床研究者；目标五：实施全面、严格、质量提升 方法，利用新颖的工具来规划、培训学员和导师评估，跟踪里程碑以及 成功的结果指标。